SEC Comment Letter for Virtuoso Surgical, Inc. (CIK 0001742075) — Jun 23, 2022
Virtuoso Surgical, Inc. (CIK 0001742075)
Date: June 23, 2022 · CIK: 0001742075 · Accession: 0000000000-22-006792
AI Filing Summary & Sentiment
File numbers found in text: 024-11915
Letter
United States securities and exchange commission logo June 23, 2022 C. Mark Pickrell, Esq. General Counsel Virtuoso Surgical, Inc. 5701 Old Harding Pike, Suite 200 Nashville, Tennessee 37205 Re:Virtuoso Surgical, Inc. Offering Statement on Form 1-A Filed June 21, 2022 File No. 024-11915 Dear Mr. Pickrell: This is to advise you that we do not intend to review your offering statement. We will consider qualifying your offering statement at your request. If a participant in your offering is required to clear its compensation arrangements with FINRA, please have FINRA advise us that it has no objections to the compensation arrangements prior to qualification. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. We also remind you that, following qualification of your Form 1-A, Rule 257 of Regulation A requires you to file periodic and current reports, including a Form 1-K which will be due within 120 calendar days after the end of the fiscal year covered by the report. Please contact Tim Buchmiller at (202) 551-3635 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc: David R. Clay, Esq.
Show Raw Text
United States securities and exchange commission logo
June 23, 2022
C. Mark Pickrell, Esq.
General Counsel
Virtuoso Surgical, Inc.
5701 Old Harding Pike, Suite 200
Nashville, Tennessee 37205
Re:Virtuoso Surgical, Inc.
Offering Statement on Form 1-A
Filed June 21, 2022
File No. 024-11915
Dear Mr. Pickrell:
This is to advise you that we do not intend to review your offering statement.
We will consider qualifying your offering statement at your request. If a participant in
your offering is required to clear its compensation arrangements with FINRA, please have
FINRA advise us that it has no objections to the compensation arrangements prior to
qualification.
We remind you that the company and its management are responsible for the accuracy
and adequacy of their disclosures, notwithstanding any review, comments, action or absence of
action by the staff. We also remind you that, following qualification of your Form 1-A, Rule 257
of Regulation A requires you to file periodic and current reports, including a Form 1-K which
will be due within 120 calendar days after the end of the fiscal year covered by the report.
Please contact Tim Buchmiller at (202) 551-3635 with any questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc: David R. Clay, Esq.